Anulid® Tablet 400 mg: Each film-coated tablet contains Linezolid USP 400 mg.
Anulid® Tablet 600 mg: Each film-coated tablet contains Linezolid USP 600 mg.
Anulid® Powder for Suspension: After reconstitution, each 5 mL contains Linezolid USP 100 mg.
Linezolid is a synthetic antibacterial agent from the oxazolidinones class, effective against certain Gram-positive and Gram-negative bacteria. It works by inhibiting bacterial protein synthesis through binding to the 23S ribosomal RNA of the bacterial ribosome, preventing the formation of a functional 70S initiation complex. It is bacteriostatic for enterococci and staphylococci and bactericidal for most streptococci.
Linezolid is indicated for the treatment of:Vancomycin-Resistant Enterococcus faecium infections, including those with bacteremia.Nosocomial pneumonia caused by Staphylococcus aureus (both methicillin-susceptible and -resistant strains) or Streptococcus pneumoniae (including multi-drug resistant strains). Complicated skin and skin structure infections, including diabetic foot infections (without osteomyelitis), caused by Staphylococcus aureus (methicillin-susceptible and methicillin-resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes. Community-acquired pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains) or Staphylococcus aureus (methicillin-susceptible strains).
Parenteral to Oral Switch: Patients can switch from parenteral to oral formulations when clinically appropriate, as Linezolid has 100% oral bioavailability. No dose adjustment is required.
Injection: Administered over 30-120 minutes.
Oral Tablet/Suspension: May be taken with or without food.
Reconstitution of Oral Suspension:
Shake the bottle to loosen the powder.
Add 65 mL (using the provided cup) of boiled and cooled water in two portions.
Shake well after each addition until the powder is completely suspended.
The reconstituted suspension should be used within 21 days. Shake the bottle well before each use and store in a cool, dry place.
Known hypersensitivity to Linezolid or any component of the formulation.
Use in patients taking monoamine oxidase inhibitors (e.g., Phenelzine, Isocarboxazid) or within two weeks after stopping them.
Not recommended for patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis, carcinoid syndrome, or taking sympathomimetic agents, vasopressors, dopaminergic agents, serotonin reuptake inhibitors, tricyclic antidepressants, serotonin 5-HT1 receptor agonists, meperidine, or buspirone.
Monitor for recurrent nausea, vomiting, acidosis, or low bicarbonate during treatment.
Linezolid may interact with serotonergic agents, leading to serotonin syndrome. Watch for cognitive dysfunction, hyperreflexia, hyperpyrexia, and incoordination.
If visual changes occur, prompt ophthalmic evaluation is recommended.
Convulsions have been reported, particularly in patients with a history of seizures or risk factors.
Common: Diarrhea, headache, nausea.
Others: Oral and vaginal moniliasis, hypertension, dyspepsia, abdominal pain, pruritus, tongue discoloration.
Pregnancy Category C: Linezolid should only be used during pregnancy if the benefits justify the risks to the fetus.
It is not known whether Linezolid is excreted in breast milk; use with caution during breastfeeding.
Monoamine Oxidase Inhibition: Linezolid is a reversible, nonselective MAO inhibitor. It can interact with adrenergic and serotonergic agents.
Adrenergic Agents: May enhance the pressor response to indirect sympathomimetic agents.
Serotonergic Agents: Watch for serotonin syndrome if used concurrently.
No reported cases of overdose. Supportive care is recommended. Approximately 30% of Linezolid is removed by haemodialysis over 3 hours.
Store below 30°C in a dry place, away from light and moisture.
